Latest Insider Transactions at Glycomimetics Inc (GLYC)
This section provides a real-time view of insider transactions for Glycomimetics Inc (GLYC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of GLYCOMIMETICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of GLYCOMIMETICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 21
2024
|
Edwin Rock Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
115,000
+14.46%
|
$0
$0.27 P/Share
|
|
Jun 20
2024
|
Edwin Rock Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
190,000
+25.15%
|
$0
$0.25 P/Share
|
|
Jun 18
2024
|
Brian M. Hahn SVP Finance, CFO |
BUY
Open market or private purchase
|
Direct |
17,500
+19.85%
|
$0
$0.25 P/Share
|
|
Mar 29
2024
|
Mark Alan Goldberg |
BUY
Grant, award, or other acquisition
|
Direct |
4,584
+15.59%
|
$13,752
$3.0 P/Share
|
|
Mar 29
2024
|
Rachel K. King |
BUY
Grant, award, or other acquisition
|
Direct |
3,334
+0.64%
|
$10,002
$3.0 P/Share
|
|
Mar 29
2024
|
Daniel M Junius |
BUY
Grant, award, or other acquisition
|
Direct |
5,209
+5.02%
|
$15,627
$3.0 P/Share
|
|
Dec 29
2023
|
Mark Alan Goldberg |
BUY
Grant, award, or other acquisition
|
Direct |
5,827
+22.35%
|
$11,654
$2.36 P/Share
|
|
Dec 29
2023
|
Rachel K. King |
BUY
Grant, award, or other acquisition
|
Direct |
4,238
+0.82%
|
$8,476
$2.36 P/Share
|
|
Dec 29
2023
|
Patricia S Andrews |
BUY
Grant, award, or other acquisition
|
Direct |
5,191
+8.14%
|
$10,382
$2.36 P/Share
|
|
Sep 30
2023
|
Mark Alan Goldberg |
BUY
Grant, award, or other acquisition
|
Direct |
9,167
+38.87%
|
$9,167
$1.5 P/Share
|
|
Sep 30
2023
|
Rachel K. King |
BUY
Grant, award, or other acquisition
|
Direct |
6,667
+1.3%
|
$6,667
$1.5 P/Share
|
|
Sep 30
2023
|
Patricia S Andrews |
BUY
Grant, award, or other acquisition
|
Direct |
8,167
+13.26%
|
$8,167
$1.5 P/Share
|
|
Sep 22
2023
|
Edwin Rock Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
30,403
+7.49%
|
$30,403
$1.38 P/Share
|
|
Sep 21
2023
|
Edwin Rock Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
35,000
+9.21%
|
$35,000
$1.38 P/Share
|
|
Jun 01
2023
|
Scott Koenig |
BUY
Exercise of conversion of derivative security
|
Direct |
21,000
+36.36%
|
$0
$0.6 P/Share
|
|
May 17
2023
|
Brian M. Hahn SVP Finance, CFO |
SELL
Open market or private sale
|
Direct |
3,700
-6.51%
|
$3,700
$1.95 P/Share
|
|
May 10
2023
|
Daniel M Junius |
BUY
Open market or private purchase
|
Direct |
30,000
+24.34%
|
$30,000
$1.56 P/Share
|
|
May 08
2023
|
Bruce S Johnson SVP & Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
13,500
+8.85%
|
$13,500
$1.57 P/Share
|
|
Feb 24
2023
|
Invus Public Equities, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
100,000
+1.15%
|
$100,000
$1.7 P/Share
|
|
Feb 23
2023
|
Invus Public Equities, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
200,000
+2.3%
|
$200,000
$1.75 P/Share
|
|
Feb 22
2023
|
Invus Public Equities, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
150,000
+1.78%
|
$150,000
$1.79 P/Share
|
|
Feb 21
2023
|
Invus Public Equities, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
50,000
+0.61%
|
$50,000
$1.85 P/Share
|
|
Feb 17
2023
|
Invus Public Equities, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
200,000
+2.41%
|
$200,000
$1.7 P/Share
|
|
Feb 16
2023
|
Invus Public Equities, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
315,266
+3.84%
|
$315,266
$1.68 P/Share
|
|
Feb 15
2023
|
Invus Public Equities, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,000,000
+11.66%
|
$2,000,000
$2.16 P/Share
|
|
Feb 09
2023
|
Invus Public Equities, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
11,451
+0.17%
|
$34,353
$3.24 P/Share
|
|
Jan 27
2023
|
Scott Koenig |
BUY
Exercise of conversion of derivative security
|
Direct |
10,500
+40.0%
|
$21,000
$2.55 P/Share
|
|
Jan 26
2023
|
Scott D Sandell > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,000,000
-37.65%
|
$9,000,000
$3.12 P/Share
|
|
Jan 25
2023
|
Scott D Sandell > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
652,016
-7.56%
|
$1,956,048
$3.26 P/Share
|
|
Jan 05
2023
|
Scott D Sandell > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
71,362
-0.82%
|
$142,724
$2.76 P/Share
|
|
Jan 04
2023
|
Scott D Sandell > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
101,984
-1.16%
|
$203,968
$2.91 P/Share
|
|
Jan 03
2023
|
Scott D Sandell > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
174,814
-1.95%
|
$349,628
$2.99 P/Share
|
|
Dec 30
2022
|
Scott D Sandell > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
121,335
-1.34%
|
$364,005
$3.02 P/Share
|
|
Dec 22
2022
|
Edwin Rock Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
110,000
+26.19%
|
$220,000
$2.25 P/Share
|
|
Nov 17
2022
|
Daniel M Junius |
BUY
Open market or private purchase
|
Direct |
20,000
+24.02%
|
$20,000
$1.87 P/Share
|
|
Nov 15
2022
|
Edwin Rock Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
100,000
+33.33%
|
$100,000
$1.66 P/Share
|
|
Nov 14
2022
|
Edwin Rock Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
100,000
+50.0%
|
$100,000
$1.43 P/Share
|
|
Nov 11
2022
|
Armand Girard SVP, Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
6,500
+18.23%
|
$6,500
$1.05 P/Share
|
|
Nov 11
2022
|
John L. Magnani SVP of Research, CSO |
BUY
Open market or private purchase
|
Direct |
45,045
+10.96%
|
$45,045
$1.17 P/Share
|
|
Nov 11
2022
|
Brian M. Hahn SVP Finance, CFO |
BUY
Open market or private purchase
|
Direct |
20,000
+26.03%
|
$20,000
$1.06 P/Share
|
|
Nov 11
2022
|
Harout Semerjian Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+50.0%
|
$25,000
$1.29 P/Share
|
|
Nov 11
2022
|
Timothy R Pearson |
BUY
Open market or private purchase
|
Direct |
19,400
+44.04%
|
$19,400
$1.29 P/Share
|
|
Mar 09
2022
|
Brian M. Hahn SVP Finance, CFO |
SELL
Open market or private sale
|
Direct |
2,917
-7.34%
|
$2,917
$1.09 P/Share
|
|
Mar 09
2022
|
Armand Girard SVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
2,339
-9.36%
|
$2,339
$1.09 P/Share
|
|
Mar 09
2022
|
John L. Magnani SVP of Research, CSO |
SELL
Open market or private sale
|
Direct |
3,227
-1.0%
|
$3,227
$1.09 P/Share
|
|
Nov 16
2021
|
Patricia S Andrews |
BUY
Open market or private purchase
|
Direct |
40,000
+46.92%
|
$80,000
$2.05 P/Share
|
|
May 18
2021
|
Timothy R Pearson |
BUY
Grant, award, or other acquisition
|
Direct |
5,250
+50.0%
|
-
|
|
May 18
2021
|
Scott Koenig |
BUY
Grant, award, or other acquisition
|
Direct |
5,250
+50.0%
|
-
|
|
May 18
2021
|
Mark Alan Goldberg |
BUY
Grant, award, or other acquisition
|
Direct |
5,250
+50.0%
|
-
|
|
May 18
2021
|
Patricia S Andrews |
BUY
Grant, award, or other acquisition
|
Direct |
5,250
+50.0%
|
-
|